Ballew Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Ballew Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-250	Closed	-$6.41K	–	116
2024 Q4	$6.41K	Buy	+250	New	+$5.2K	﹤0.01%	104

Other funds holding TNXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CIBC Asset Management Toronto, Ontario, Canada $40.9B AUM 35.96% 1-Year Est. Return

Ballew Advisors's TNXP Position: Q1 2025 in Review

Ballew Advisors sold out of Tonix Pharmaceuticals (TNXP) in Q1 2025, closing a stake of 250 shares — an estimated $6.41K sold.

Ballew Advisors first reported a position in TNXP in Q4 2024 and held it in 1 quarter. The position peaked at $6.41K in Q4 2024. 26 funds tracked by Wall St. Rank hold TNXP as of Q1 2025.

Ballew Advisors reported no remaining Tonix Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Ballew Advisors sold 250 Tonix Pharmaceuticals shares in Q1 2025, an estimated $6.41K.
Ballew Advisors first reported a position in Tonix Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Ballew Advisors's Tonix Pharmaceuticals position peaked at $6.41K in Q4 2024.
26 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2025.

Based on Ballew Advisors's 13F filing for Q1 2025, filed 16 Apr 2025.